Daemon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Net Worth 12.37%
- Total Assets 113.41%
About Daemon Pharma
Daemon Pharma Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 May 2017 (Seven years and nine months 21 days old ). Its registered office is in Pune, Maharashtra, India.
The Corporate was formerly known as Sonvision Pharma Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Santosh Jadhav, Sanjay Kharge, and Pramod Suryawanshi serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999PN2017PTC170287
- Company No.
170287
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
What products or services does Daemon Pharma Private Limited offer?
Daemon Pharma Private Limited offers a wide range of products and services, including Vitamins & Supplements, Vitamins A-Z.
Who are the key members and board of directors at Daemon Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Jadhav  | Director | 03-May-2017 | Current |
| Sanjay Kharge | Director | 03-May-2017 | Current |
| Pramod Suryawanshi | Director | 21-Nov-2018 | Current |
Financial Performance of Daemon Pharma.
Daemon Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 12.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Daemon Pharma?
In 2020, Daemon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Daemon Pharma?
Unlock and access historical data on people associated with Daemon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daemon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daemon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.